Skip to main content
. Author manuscript; available in PMC: 2017 Oct 24.
Published in final edited form as: Nat Chem Biol. 2017 Apr 24;13(6):681–690. doi: 10.1038/nchembio.2360

Fig 6. In vivo assessment of the immunomodulatory potential of crizotinib.

Fig 6

(a) Immunohistochemistry imaging of SW480 xenograft tumors stained with anti-human MHC-1 (40x images, scale bar 20μm) and (b) image quantification of MHC-I expression levels for 24-images per group, after treatment with 50mg/kg p.o. vehicle, (R)- or (S)-crizotinib. (c) MFI of MHC-I expression on CD34+ blasts and (d) DMSO-relative interaction scores between CD33+ blasts and CD3+ T-cells after crizotinib treatment in PBMCs of a patient diagnosed with a post-CMML AML. (a-b) Staining was performed on 3 tumors per group, 8 images each; selected images are representative of average. (c-d) are representative experiments of at least three repeats. (b-d) Significance was calculated by a t-test, and boxplots or standard error of means are shown.